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ess: antoine.magnan@mSummary Assessment tools are needed to monitor asthma control and to detect
exacerbations before the alteration of functional parameters and the occurrence of
symptoms. The ability to effectively monitor asthma control would enable clinicians
to increase corticosteroid dose or to stop corticosteroid tapering before symptoms
occur. As a few severe exacerbations are expected per year in treated patients,
these tools must be suitable for long-term use. They must also be reproducible,
acceptable to patients and be non-invasive. Tools currently available to assess
asthma control include assessment of: clinical parameters (e.g. nocturnal awaken-
ings; bronchodilator intake; symptom scores); lung function (e.g. peak expiratory
flow and forced expiratory volume in 1 s); subjective parameters of asthma control
(e.g. asthma control questionnaire (ACQ)); bronchial hyper-responsiveness; eosino-
philia in induced sputum; and exhaled nitric oxide (NO) concentration. Clinical
symptoms, lung function and the ACQ have proved to be inadequate markers of
asthma control, as changes in these parameters occur at the same time as symptom
manifestation. By contrast, sputum eosinophilia and exhaled NO concentrations are
truly predictive of asthma exacerbations; monitoring these parameters are useful in
preventing exacerbations from occurring in the first instance. They also assess, and
help to achieve asthma control in the long term.
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The symptoms of most asthmatic patients can be
adequately controlled by currently available ther-
apy, primarily inhaled corticosteroids (ICSs). How-
ever, a loss of asthma control after some months
occurs in a proportion of asthmatic patients,
leading to exacerbations, hospitalisation(s) and
treatment with oral corticosteroids, which poten-
tially have long-term adverse effects. With treat-
ment, asthma control is regained, but the symptomed.
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Asthma control S17baseline becomes elevated, reflecting the airway
remodelling component of asthma. In these pa-
tients, exacerbations can be triggered by allergen
or pollutant exposure, tobacco smoke or infection.
In many cases, non-compliance with treatment is a
factor in loss of asthma control. However, in some
cases, no triggering factor is found. Tapering of
corticosteroid treatment in these patients is
especially difficult since it represents a risk of
exacerbation.
Asthma control needs to be monitored in the
long-term. Long-term studies are more indicative
of ‘real life’ situations and allow the assessment of
asthma control, exacerbations and airway remodel-
ling. In ‘real life’ situations patients are exposed to
unscheduled triggering factors such as allergens,
tobacco smoke and other pollutants, may have
concomitant diseases (e.g. rhinitis, gastroeosopha-
geal reflux) and are more than likely to be non-
compliant with therapy. In a recent long-term
study, Pauwels and colleagues1 showed that in
patients with mild asthma, control was achieved
following treatment with inhaled budesonide.
However, even these patients with mild asthma
experienced an exacerbation of their disease whilst
on ICS therapy.1 Patients with severe asthma have
an exacerbation several times a year. Clearly, there
is an unmet clinical need in these patients to
develop tools to assess the long-term control of
asthma and also to predict when loss of control is
about to occur, before symptoms and impaired lung
function occur.Tools to monitor asthma control
Early detection of loss of asthma control is
important as it enables: (1) effective prophylactic
therapy to be given before symptoms become
apparent and also (2) allows the determination of
the lowest effective dose of treatment. Fig. 1a
shows how monitoring asthma control enables
therapy to be given before symptoms present.
Without a marker of asthma control patients’
asthma often exacerbates and is usually treated
with oral corticosteroids (treatment 2) to regain
control of the disease. Once the exacerbation has
subsided add-on therapy, such as a long-acting b2-
agonist (LABA), is usually initiated to maintain
control (treatment 3). Using a marker which is
indicative of imminent loss of asthma control
enables prophylactic therapy to be initiated (treat-
ment 10) before symptoms manifest. Maintenance
therapy can then be achieved on a lower dose.
However, it is essential that the marker chosen toindicate the status of asthma control is detectable
before symptoms present (Fig. 1a).
Markers of asthma control can also be used to
determine the lowest efficient dose of ICSs (Fig.
1b). Once control of asthma has been achieved for
3 months (treatment 3), asthma management
guidelines recommend reducing the number of
add-on therapies (treatment 2) and gradually
reducing the corticosteroid dose (treatment 1).
Patients who re-exacerbate during steroid tapering
are frequently reassigned to a therapy regimen
with proven efficacy which attained control of their
asthma in the past (e.g. ICSs and LABAs; treatment
3). Once control has been reachieved, add-on
therapies can again be removed but steroid
tapering (treatment 1) avoided. A good
predictor of impending loss of asthma control
would indicate that loss of control is about to
occur before symptoms have become apparent
during steroid tapering (Fig. 1b). In this instance a
prophylactic therapy (treatment 10) could be
introduced thus avoiding the occurrence of symp-
toms and maintenance can be achieved on a lower
dose.
Many tests to assess asthma control are now
available and include assessment of clinical para-
meters (e.g. nocturnal awakenings, bronchodilator
intake), lung function (e.g. forced expiratory
volume in 1 s (FEV1); peak expiratory flow (PEF));
subjective parameters (e.g. asthma control ques-
tionnaire (ACQ)); bronchial hyper-responsiveness
(BHR); induces sputum (IS) eosinophilia; and ex-
haled nitric oxide (NO) concentration. The ideal
test to monitor asthma control should be safe, non-
invasive and reproducible. The selected marker of
asthma control should be predictive of an exacer-
bation and occur before symptoms present.Clinical assessment
Clinical parameters frequently used to assess
asthma control include nocturnal awakenings,
bronchodilator intake and symptom scores. How-
ever, these parameters do not predict loss of
asthma control, as clearly if they are elevated
then patients are already experiencing symptoms,
a fact which was highlighted by Tattersfield and
colleagues.2 They examined change in PEF, symp-
toms, and use of rescue b-agonists during the 425
severe exacerbations that occurred during a 12-
month parallel group study in which low and high
doses of budesonide with and without formoterol
were compared in patients with asthma. Results
showed that reduction in PEF was a late indicator of
loss of asthma control, occurring at the same time
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Figure 1 Schematic representation of how tools to assess loss of asthma control can (a) prevent the occurrence of
exacerbations, and (b) determine the lowest effective dose of ICSs.
A. MagnanS18as symptoms.2 Exacerbations were characterised by
a gradual fall in PEF over several days, followed by
more rapid changes over 2–3 days. An increase in
symptoms and rescue b-agonist use occurred in
parallel, and both the severity and time course of
the changes were similar in all treatment groups.2
(Fig. 2)
Similarly, reduction in FEV1 represents an asth-
matic symptom and so cannot be considered as an
early indicator of exacerbation.3,4 Pizzichini and
colleagues4 induced exacerbations by lowering the
dose of ICSs in prednisolone-dependent asthmatics
and showed that reduction of prednisone treatment
evoked a severe airway eosinophilic inflammatoryresponse. A drop in FEV1 occurred 6 weeks after
sputum eosinophilia was detected suggesting that
sputum examination, but not FEV1 assessment, may
be useful in identifying the minimum regular dose
of prednisone required in these patients.4Questionnaires
Daily symptoms, PEF, and medication diaries are
often used in clinical trials of treatments for
asthma on the assumption that they provide a
better estimate of clinical status than does a
questionnaire completed in the clinic. Juniper and
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Figure 2 Drop in PEF rate occurs at the same time as occurrence of symptoms. Reprinted with permission from
Tattersfield et al.2
Asthma control S19colleagues5 conducted a study comparing the
measurement properties of the clinic-completed
ACQ with those of the Asthma Control Diary (ACD)
in 50 adults with symptomatic asthma. The diary is
composed of questions and response options which
are almost identical to those of the ACQ, but uses
PEF instead of FEV1 as the measure of airway
caliber. Results showed high concordance between
the questionnaire and diary, but both responsive-
ness and reliability were better with the ACQ. Both
the ACQ and the ACD were valid instruments for
measuring asthma control, but the questionnaire
had slightly better discriminative and evaluative
measurement properties than does the diary.5
However, in terms of predictive power, both the
ACQ and the ACD are late indicators of loss of
asthma control reflecting the occurrence of symp-
toms rather than their imminent arrival.Bronchial hyper-responsiveness
Non-specific BHR decreases when asthma is con-
trolled and increases before an exacerbation of
asthma. Jatakanon and colleagues6 showed that
BHR decreased following treatment with budeso-
nide (100–1600 mg) in a dose-responsive manner in
mild stable steroid naı¨ve asthmatic patients. There
were also significant improvements in FEV1 follow-
ing 400 and 1600 mg budesonide which was accom-
panied by significant reductions in eosinophil
numbers in induced sputum (IS). Concentrations
of exhaled NO were reduced following each
budesonide dose, while BHR was improved only
with 1600 mg budesonide.6 However, the procedureused to measure BHR can in itself produce
symptoms of asthma and so results are difficult to
interpret. In addition, BHR and exhaled NO may not
reflect the control of airway inflammation as
accurately as the number of eosinophils in sputum.
Sont and colleagues7 used measurement of BHR
to assess control in stable asthmatic patients (n=75)
whilst tapering ICS dose. One group was treated
with ICSs based on the results of BHR and the other
group treated according to asthma management
guidelines. Patients treated according to the BHR
strategy had a 1.8-fold lower rate of mild exacer-
bations than did patients in the reference strategy
group and exhibited a clinically significant improve-
ment of 200ml in their FEV1 (Fig. 3a).
7 However,
the dose of ICSs in the BHR group was twice that
observed in the reference strategy group (Fig. 3b)
indicating that monitoring BHR may reduce the
threshold of ICS increase, leading to over-treat-
ment in some patients. In a crossover study in
patients with mild-to-moderate asthma BHR to
adenosine monophosphate (AMP) was an early and
sensitive indicator of the beneficial anti-inflamma-
tory effect of budesonide.8 A significant change of
1.670.3, 2.270.3, and 2.870.3 doubling doses of
PC(20) AMP was observed at 1, 4, and 6 weeks,
respectively, in the course of budesonide treat-
ment.8Eosinophilia and exhaled nitric oxide
Treatment decisions in asthma are usually based on
assessments of symptoms and simple measures of
lung function, which do not relate closely to
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Figure 4 Concentration of exhaled NO at baseline is not
a good marker of exacerbation risk. Reprinted with
permission from Jatakanon et al.3
Figure 5 Number of eosinophils in IS is a good marker of
exacerbation risk. Mac: macrophages; Neut: neutrophils;
Eos: eosinophils; Lymph: lymphocytes. Reprinted with
permission from Jatakanon et al.3
Figure 3 Using airway hyper-responsiveness (AHR) in-
stead of asthma management guidelines to monitor
asthma control in stable asthmatic patients results in
(a) lower incidence of exacerbations as assessed by drop
in FEV1 but, (b) higher dose of ICSs. Reprinted with
permission from Sont et al.7
A. MagnanS20underlying eosinophilic airway inflammation.
Counting the number of eosinophils in IS has been
used to monitor the adjustment of therapy in
asthmatics.9 Monitoring IS eosinophil counts allows
an inflammatory diagnosis which specifically moni-
tors ICS use. Indeed, the persistence of a significant
bronchial eosinophilia in treated patients reflects
insufficiency of ICS treatment, and/or poor com-
pliance with the treatment regimen.10 However, IS
is a time-consuming procedure and is not applicable
to all patients.
An alternative approach is to use a surrogate
marker of eosinophilia. Exhaled NO reflects the
eosinophilic inflammation in asthma and is easy to
monitor,11 but is probably less specific than count-
ing eosinophils directly. Although the evidence to
support the routine use of measurement of exhaled
NO in the management of patients with asthma is
limited, it may prove to be useful in assessing
adherence to treatment with ICSs, or in the
identification of patients in whom respiratory
symptoms are associated with eosinophilic airway
inflammation. In a study by Jatakanon and collea-gues,3 the dose of ICSs was reduced to 200 mg in an
attempt to induce an exacerbation in patients with
stable asthma (n=15). NO, methacholine challenge
and eosinophils in sputum were measured twice a
week for 8 weeks in these patients. At the end of
the study seven patients had developed an exacer-
bation and eight had not. Baseline exhaled NO did
not predict exacerbation risk (Fig. 4). The only
significant difference between the two groups at
baseline was a higher baseline sputum eosinophil
count in subjects with subsequent exacerbations
(Fig. 5), and this elevation was noted before any
functional alterations accompanying exacerbations
occurred.3 The increases in sputum eosinophils and
exhaled NO were correlated with decreases in
airway function, including decreases in morning
PEF and FEV1.
3 Multiple regression analysis sug-
gested that the change in sputum eosinophils is a
potentially useful marker in predicting loss of
asthma control reflected by loss of airway function.
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Figure 6 Patients treated according to sputum eosino-
philia experience fewer exacerbations than patients
treated according to BTS guidelines. Reprinted with
permission from Green et al.9
Asthma control S21Green and colleagues9 assessed whether a
management strategy that minimised eosinophilic
inflammation reduced asthma exacerbations com-
pared with a standard management strategy.
Seventy-four patients with moderate-to-severe
asthma were randomly allocated to management
either by standard British Thoracic Society asthma
guidelines (BTS management group) or by normal-
isation of IS eosinophil count and reduction of
symptoms (sputum management group). The spu-
tum eosinophil count, incidence of severe exacer-
bations and admittance to hospital were all
significantly reduced over 12 months in the sputum
management group than in the BTS management
group (Fig. 6).9 They also showed that FEV1 and
other functional parameters were not different
between the two groups clearly indicating that
variation in FEV1 cannot be used as a marker for
potential exacerbation.9 Contrary to the findings by
Sont and colleagues7 who used BHR results as their
treatment guide, the average daily dose of inhaled
or oral corticosteroids did not differ between the
two groups.9 Taken together, these considerations
indicate that assessment of asthma control in the
long-term in asthmatics with repeated exacerba-
tions should include several complementary meth-
ods including IS, especially with regard to ICS use.Conclusions
To date IS eosinophilia is the best-validated tool
predictive of loss of asthma control. However, IS is
a time-consuming procedure and so other proce-dures are needed for routine use. Increased
bronchial responsiveness to methacholine is also
predictive of loss of asthma control, but the
procedure used to measure it is very invasive and
can itself produce symptoms of asthma. Addition-
ally, monitoring asthma control as a function of BHR
may result in over-treatment with ICS. These
procedures are certainly useful in preventing
exacerbations. They assess, and help to achieve
asthma control in the long-term. The ACQ may be
considered, but most likely changes in the ques-
tionnaire would be observed when loss of asthma
control has already occurred and patients are
experiencing symptoms. Exhaled NO is a promising
surrogate marker of asthma control although
studies are needed to assess its applicability in
the long-term assessment of asthma. Other appli-
cations of these predictive tools should be con-
sidered and include assessment of compliance and
prediction of ICS efficiency in patients with asthma.References
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